An interventional study of Conventional Right hemicolectomy (Non-CME) and Right hemicolectomy with CME+CVL in Colon Cancer, sponsored by University of Turin, Italy. Recruiting at 14 sites in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-11-14.
Sponsored by University of Turin, Italy · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 135 studies in Colonic Neoplasms with a site in Italy — 41 open to participants now, 56 under way, 8 of them phase 3. Colonic Neoplasms · Italy.
Among the 135 studies in Colonic Neoplasms with a site in Italy, this one is the 35th largest by planned enrollment of the 87 interventional ones that give a count, is one of 11 that started in 2020, is one of 29 with no phase, reaches primary completion later than 26 of the 55 other live ones, and was the 76th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →41 of the 135 studies in Colonic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Solstice Oncology, Inc. · Sites in Italy, United States, Belgium and 3 more countries
Ages 18+
Matteo Clavarezza · Sites in Italy
Ages 70–99
Incyte Corporation · Sites in Italy, United States, Argentina and 19 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Argentina and 17 more countries
Ages 18+
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · Sites in Italy
Ages 18+ · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
135 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 27
First in 1991; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 416 is above the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 222 across the 87 interventional studies, 345 across the 44 observational. Of the 58 that completed or were terminated, 9 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 135 have an industry lead sponsor. The 10 most frequent:
University of Turin, Italy is the lead sponsor of 214 studies on the registry; 35 are open to participants now.
University of Turin, Italy has 3 studies filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies in Colonic Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06567782GlaxoSmithKlineA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer | 2026-11-23 |
| NCT07153458Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de BellisIdentification of New Non-invasive, Predictive, and Diagnostic Biomarkers for Colorectal Cancer | 2026-12-01 |
| NCT05714124IRCCS San RaffaeleLiver Embolization Approaches for Tumor Management | 2026-12-31 |
| NCT05186116Azienda Ospedaliero-Universitaria di ModenaLDLT in Non Resectable Colo-rectal Cancer Liver Metastasis | 2027-01-01 |
| NCT04871399University of Turin, ItalyComplete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer | 2027-01-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 135 studies in Colonic Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An Italian randomized controlled trial parallel-group in patients with a malignant tumor of the right or proximal transverse colon requiring right hemicolectomy.
This study aims to compare the Complete Mesocolic Excision With Central Vascular Ligation (CME+CVL) with the standard (non-CME) right hemicolectomy in patients with right or proximal transverse colon cancer stage II-IV(AJCC 8th edition) to determine the short and long term outcomes in terms of disease-free survival (DFS) as a primary endpoint, and safety, oncologic outcomes, quality of surgery and quality of life (QoL) as secondary endpoints.
Eligible patients will be randomized with a 1:1 ratio between CME + CVL vs standard non-CME right colectomy. The randomization sequence will be generated centrally by a computed algorithm and kept concealed to investigators.
The Right colectomy with CME + CVL includes the removal of the accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia. Despite the surgical approach and the type of procedure adopted, the operation should be strictly conducted following the general rules for colorectal oncologic resection, particularly as concerns proximal and distal margins length and lymph node retrieval.
All surgical approaches (open, laparoscopic, or robotic) will be allowed while the type of anastomosis performed and drain placement will be up to the surgeon's discretion.
Demographic, baseline, perioperative and postoperative characteristics will be analyzed as well.
The study expected to last six and a half years, of which one and a half years for recruiting 416 patients, 208 each arm, with five years of follow-up. Patients will be followed up at 1, 4, 12, 24, 36, and 60 months postoperatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will undergo conventional non-CME procedure.
Procedure: Conventional Right hemicolectomy (Non-CME)
Patients will undergo Right hemicolectomy CME+CVL procedure.
Procedure: Right hemicolectomy with CME+CVL
Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.
Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly: * The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery * The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery. The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance.
Disease-free survival at 3 years
The length of time after surgery without any signs or symptoms of local or distant recurrence.
Time frame: 3 Years.
Safety-Operative time.
Total time from incision to skin closure expressed in minutes.
Time frame: Intraoperative
Safety-Intraoperative blood loss.
Defined by the volume drained in cm2 into aspiration systems and weight of gauzes, calculated, subtracting the weight of the dry gauzes and volume of saline solution used for irrigation.
Time frame: Intraoperative
Safety-Intraoperative blood transfusion.
Defined as the number of red blood cells, platelets, or plasma units transfused during the intraoperative time.
Time frame: Intraoperative
Safety- Intraoperative Complications.
Defined as any deviation from the ideal intraoperative course occurring during the operative time, Using the Classification of Intraoperative Complications(CLASSIC).
Time frame: Intraoperative
Early postoperative complications.
Number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.
Time frame: 30 postoperative days.
Late postoperative complications.
The number of patients with any deviation from the normal postoperative course grading by The Clavien-Dindo classification.
Time frame: From the 31st postoperative days to the end of the study.
Safety- Length of stay.
Defined as the length of an inpatient episode of care, calculated from the day of operation to the first discharge and based on the number of nights spent in the hospital.
Time frame: 30 Days.
Safety- Postoperative mortality rate.
The all-cause death rate, within 30 days after surgery in or out of the hospital.
Time frame: 30 Days.
Overall Survival at 3 years
Defined as the time from random assignment to the date of death due to any cause.
Time frame: 3 Years.
Overall Survival at 5 years.
Defined as the time from random assignment to the date of death due to any cause.
Time frame: 5 Years.
Disease-free survival.
Defined as the length of time after Surgical treatment (CME+CVL or Conventional non-CME procedure) that the patient survives without any signs or symptoms of colon cancer.
Time frame: 5 Years.
Other Oncologic outcomes.
The number of positive, negative, and total lymph nodes harvested, Quality of surgery specimen, quality of life by EORTC specific Questionnaires
Time frame: 30 Days.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jul 2020 (actual). Primary completion is estimated for Jan 2027, 77 months after the start.
Of 382 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 55. This study's planned 77 months is above that.
Counting every sponsor, half of 404 studies reached it within 30 months; a quarter within 16 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.